Tumor Immunology and Immunotherapy

by Rees, Robert C.

• ISBN13: 9780199676866
• ISBN10: 0199676860
• Edition: 1st
• Format: Hardcover
• Copyright: 2014-07-29
• Publisher: Oxford University Press

Summary

Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management.

Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity.

The book examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.

Author Biography

Robert C. Rees, Director and Professor of Tumour Biology, The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK

Table of Contents

1. Adaptive T-cell immunity and tumor antigen recognition, Pedro Romero and Pierre G. Coulie
2. Impact of aging and body mass on cancer immunotherapy outcomes, Gail D. Sckisel, Arta M. Monjazeb, Annie Mirsoian, Anthony E. Zamora, Steven Grossenbacher, and William J. Murphy
3. The potential of natural killer cells in cancer immunotherapy, Thomas C.C. Tan, Jean-Marc Doisne and Francesco Colucci
4. The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy, Russell Hughes and Munitta Muthana
5. "Hard" and "soft" loss of MHC class I expression in cancer cells, Natalia Aptsiauri, Angel M. Garcia-Lora, Federico Garrido
6. Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses, A.G. Dalgleish
7. Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation., Pratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau, and Suzanne Ostrand-Rosenberg
8. Triggering death receptors as a means of inducing tumoricidal activity, Thomas J. Sayers and Neil A Cross
9. Identification of tumor antigens for clinical evaluation, Jayakumar Vadakekolathu, Stephanie B. McArdle, David J. Boocock, and Amanda Miles
10. Viral antigens as targets for prophylactic and therapeutic intervention in cancer, Peter L. Stern and Kenneth Oguejiofor
11. HER-2/neu as a target for vaccine and antibody directed therapies, Constantin N. Baxevanis and Sonia A. Perez
12. Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model, Matteo Bellone, Sara Martina Parigi, and Elena Jachetti
13. Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy, Per thor Straten, Dave Schrama, Jurgen C. Becker and Mads Hald Andersen
14. Predictive biomarkers to better select patients for cancer immunotherapy, M. Strioga and E. Tartour
15. Viral platforms for expression of tumour antigens in cancer immunotherapy, Karishma Rajani, Vanessa Alonso-Camino, Nicolas Boisgerault, Richard Vile
16. Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies, Paul Moss
17. DNA vaccines, L. G. Durrant, W. Xue, L. R. Machado, R. L. Metheringham, and V. A. Brentville
18. Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA), Uzoma K. Iheagwaraa, Pamela L. Beattya, Chan Su-Wan Biancaa, Lora H. Rigattid, Ted Ross, and Olivera J. Finn
19. Vaccination against myeloid leukaemias using newly defined antigens, Susanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-Ann Guinn
20. Immune-checkpoint blockade in cancer immunotherapy, Patrick A. Ott and F. Stephen Hodi
21. Multi-peptide cancer vaccines for clinical application, Harpreet Singh-Jasuja, Toni Weinschenk, and Steffen Walter
22. Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma, Marco Donia, Eva Ellebaek, and Inge Marie Svane
23. Chimeric antigen receptor gene therapy in cancer, John S. Bridgeman and David E. Gilham
24. The vaccinal effect of monoclonal antibodies in cancer therapy, Claire Deligne, Sophie Siberil, and Jean-Luc Teillaud
25. Antibody therapies: defining appropriate cell surface epitopes for targeting tumours, Gabriele Multhoff and Michael Stanglmaier
26. Adoptive lymphocyte (stem cell) therapy in cancer, Sophie Derniame and Aurore Saudemont
27. Cancer Stem Cells (CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity Challenges Immunotherapy, Tarik Regad and Morgan G. Mathieu
28. Immune escape and aging of the immune system compromises the immune response to tumor antigens, Ludmila Muller and Graham Pawelec